A Case of Lung Adenocarcinoma With Concurrent EGFR Mutation and ALK Fusion Combined With Literature Review

Clinical Case Reports 2026 Open access

Read full text
Authors: Y J Chen, Fei Qi, Yixin Zeng, Jingwen Tan, Mingming Hu, Hongmei Zhang, Tongmei Zhang
DOI: 10.1002/ccr3.71749
Cited by: 1
References: 8

Abstract

This case underscores the critical importance of retesting for resistant mechanisms, such as EML4-ALK fusion, in patients with EGFR-mutant lung adenocarcinoma who experience rapid progression on EGFR-tyrosine kinase inhibitor (TKI) therapy. Early identification of such co-alterations and an immediate switch to alectinib can lead to rapid and sustained clinical improvement.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Clinical Case Reports
Publisher
Wiley
Volume
14
Issue
1
Pages
e71749–e71749
Publication date
1 January 2026
Language
EN